Components of the diff use endocrine system of the gastrointestinal tract and nonalcoholic fatty liver disease: interconnections and mutual infl uences
https://doi.org/10.31146/1682-8658-ecg-177-5-53-60
Abstract
Objective: To study the interconnections and mutual infl uences of the components of the diffuse endocrine system of the gastrointestinal tract and non-alcoholic fatty liver disease (NAFLD).
Materials and methods: 138 patients with NAFLD and intestinal pathology, 36 patients without intestinal dysfunction were examined. The morphometric indicators of the expression of colonocytes immunopositive to the vascular endothelial growth factor, as well as to leptin, were compared with the clinical and endoscopic features of the colon and liver, and the functional and structural parameters of the liver were evaluated. Correlations of the studied indicators are revealed. A mathematical model is proposed that takes into account, along with the functional characteristics of the liver, structural, immunohistochemical, and morphometric parameters of the colon mucosa, which allow predicting the stage of liver fi brosis.
Results: It was established that NAFLD is characterized by a dysregulation of diff use endocrine system parameters, which makes a certain contribution both to the formation of structural changes in the colon and to the progression of liver fi brosis.
About the Authors
I. V. Kozlova
Federal State Institution of Higher Professional Education “Saratov State Medical University n. a. V. I. Razumovsky” Ministry of Health of the Russian Federation. Department of therapy, gastroenterology and pulmonology
Russian Federation
Irina V. Kozlova, head of the Department of Therapy, Gastroenterology and Pulmonology, MD, Professor
Russian Federation
Irina V. Kozlova, head of the Department of Therapy, Gastroenterology and Pulmonology, MD, Professor
E. A. Lapteva
Federal State Budgetary Educational Institution of Higher Education “Penza State University”. Department of therapy
Russian Federation
Elena A. Lapteva, Therapy Department, Senior Lecturer
Russian Federation
Elena A. Lapteva, Therapy Department, Senior Lecturer
A. P. Bykova
Federal State Institution of Higher Professional Education “Saratov State Medical University n. a. V. I. Razumovsky” Ministry of Health of the Russian Federation. Department of therapy, gastroenterology and pulmonology
Russian Federation
Anna P. Bykova, Department of Therapy, Gastroenterology and Pulmonology, Assistant, candidate of medical sciences
Russian Federation
Anna P. Bykova, Department of Therapy, Gastroenterology and Pulmonology, Assistant, candidate of medical sciences
A. L. Pakhomova
Federal State Institution of Higher Professional Education “Saratov State Medical University n. a. V. I. Razumovsky” Ministry of Health of the Russian Federation. Department of therapy, gastroenterology and pulmonology
Russian Federation
Anna L. Pakhomova, Department of Therapy, Gastroenterology and Pulmonology, Associate Professor, candidate of medical sciences
Russian Federation
Anna L. Pakhomova, Department of Therapy, Gastroenterology and Pulmonology, Associate Professor, candidate of medical sciences
References
1. Younossi, Z. M. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease/ Z. Younossi, L. Henry. PharmacoEconomics. 2015, Vol. 33, no.12, pp. 1–9.
2. Силивончик, Н. Н. Неалкогольная жировая болезнь печени: возможности лечения/ Н. Н. Силивончик // Медицинские новости. – 2008. – № 8. –С. 8–12. Silivonchik, N. N. Non-alcoholic fatty liver disease: treatment options. Medical News. 2008, No. 8, pp. 8–12.
3. Пальцев М. А. Руководство по нейроиммуноэндокринологии. Пальцев М. А., Кветной И. М. – М.: Медицина, 2008. – 512 с. Palcev M. A., Kvetnoy I. M. Guide to Neu ro im mu no endo cri no logy. Moscow, Medicine, 2008, 512 p.
4. Мехтиев. С. Н. Эндотелиальная дисфункция как фактор прогрессирования неалкогольного стеатогепатита. Терапевтические подходы / С. Н. Мехтиев, Е. Н. Зиновьева, С. В. Соколовский // Эффективная фармакотерапия. – 2011. – № 2. – С. 36–44. Mehdiyev. S. N. Endothelial dysfunction as a factor in the progression of non-alcoholic steatohepatitis. Therapeutic approaches. Effective pharmacotherapy. 2011, No. 2, pp. 36–44.
5. Павлов, Ч. С. Современные представления о патогенезе, диагностике и лечении фиброза печени/ Ч. С. Павлов, В. Т. Ивашкин, Ю. О. Шульпекова, В. Б. Золотаревский // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2005.– Том 15, № 2. – С. 13–20. Pavlov, C. S. Modern ideas about the pathogenesis, diagnosis and treatment of liver fibrosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2005, Vol. 15, no. 2, pp. 13–20.
6. Casino, P. The role of nitric oxide in endothelium-dependent vasodilatation of hypercholesterolemic patients. Circulation. 1993, Vol. 88, pp. 2541–2547.
7. Бабенко, А. Ю. Неалкогольная жировая болезнь печени – взаимосвязи с метаболическим синдромом / А. Ю. Бабенко, М. Ю. Лаевская // Русский Медицинский Журнал. – 2018. – № 1(I). – С. 34–40. Babenko, A. Yu. Non-alcoholic fatty liver disease – relationships with metabolic syndrome. Russian Medical Journal. 2018, No. 1 (I), pp. 34–40.
8. Шварц, В. Воспаление как фактор патогенеза инсулинорезистентности и сахарного диабета 2-го типа // Терапевтический архив. – 2009. – № 10. – С. 74–80. Schwartz, V. Inflammation as a factor in the pathogenesis of insulin resistance and type 2 diabetes mellitus. Therapeutic Archive. 2009, No. 10, pp. 74–80.
9. Kitade, M. Leptinmediated neovascularization is a prerequisite for progression of nonalcoholic steato he pa ti tis in rats. Hepatology. 2006, Vol. 44, pp. 983–991.
10. Стародубова, А. В. Избыточная масса тела и ожирение как факторы риска неалкогольной жировой болезни печени/ А. В. Стародубова // Архивъ внутренней медицины. Заболевания гепатобилиарного тракта. – 2014. – № 5(19). – С. 10–20. Starodubova, A. V. Overweight and obesity as risk factors for non-alcoholic fatty liver disease. Archive of internal medicine. Hepatobiliary tract diseases. 2014, no. 5 (19), pp.10–20.
11. Stachowicz, M. Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents. 2010, Vol. 24, pp. 287–295.
12. Howard, J. M. Obesity Comorbidities Leptin and gastro-intestinal malignancies. Obes Rev, 2010, Vol. 11, № 12, pp. 863–74.
13. Drew, J. E. Symposium 3: Obesity-related cancers Molecular mechanisms linking adipokines to obesity-related colon cancer: focus on leptin. Proceedings of the Nutrition Society, 2012, Vol.71, pp. 175–180.
14. Лаптева, Е. А. Молекулярно-генетические предпосылки коморбидности жировой болезни печени и патологии толстой кишки (обзор)/ Е. А. Лаптева, И. В. Козлова // Саратовский научно-медицинский журнал, 2017. –13(1). – С. 29–34. Lapteva, E. A. Molecular genetic prerequisites for the comorbidity of fatty liver disease and colon pathology (review). Saratov Journal of Medical Scientific Research. 2017;13 (1): 29–34.
15. Щекотова, А. П. Состояние эндотелия при хронических диффузных заболеваниях печени/ А. П. Щекотова // Пермский медицинский журнал, 2009,26 (2). – С. 78–82. Schekotova, A. P. The state of the endothelium in chronic diffuse liver diseases. Perm Medical Journal. 2009;26 (2): 78–82.
16. Капланская, И. Б. Ангиогенез, межклеточные контакты и стромально-паренхиматозные взаимоотношения в норме и патологии/ И. Б. Капланская, Е. Н. Гласко, Г. А. Франк // Российский онкологический журнал. – 2005. – № 4. – С. 53–57. Kaplanskaya I. B. Angiogenesis, intercellular contacts and stromal-parenchymal relationships in norm and pathology. Russian Journal of Oncology. 2005, No. 4, pp. 53–57.
17. Senger, D. R. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res, 1986, Vol. 46, pp. 5629–5632.
18. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol, 1999, Vol.237, pp. 1–30.
19. Blachier, M. The burden of liver disease in Europe. A Review of available epidemiological data. European Association for the Study of the Liver 2013/ M. Blachier et al. J Hepatol, 2013, Vol. 58, pp. 593–608.
20. Ивашкин В.Т., Маевская М. В., Павлов Ч. С. и соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. // РЖГГК. –2016. – 2. – С. 1–20. Ivashkin V. T., Mayevskaya M. V., Pavlov Ch.S. et al. Clinical recommendations for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. RZHGGK. 2016; 2:.1–20.
21. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016;64:1388–1402.
22. Lee JH. Nonalcoholic fatty liver disease – index. EASL. 2009. Poster 59:25.
23. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4):846–54.
24. Костючек, И. Н. Методологические подходы к количественной иммуногистохимической оценке экспрессии маркеров апоптоза и пролиферации в молочной железе /И.Н. Костючек, И. Ю. Коган, И. М. Кветной Архив патологии. – 2006, 1. – C. 47–48. Kostyuchek, I. N. Methodological approaches to the quantitative immunohistochemical evaluation of the expression of apoptosis and proliferation markers in the mammary gland. Archive of Pathology. 2006; 1:47–48.
25. Liu, H. Expression and biological significance of leptin, leptin receptor, VEGF, and CD34 in colorectal carcinoma. Cell Biochem. Biophys, 2011; 60(3): 241–244.
26. Сторожаков, Г. И. Патогенетические аспекты фиброгенеза при хронических заболеваниях печени/ Г. И. Сторожаков. А. Н. Ивкова // Клинические перспективы гастроэнтерологии, гепатологии. – 2009. – № 2. – С. 3–10. Storozhakov, G. I. Pathogenetic aspects of fibrogenesis in chronic liver diseases. Clinical prospects of gastroenterology, hepatology. 2009, No. 2, pp. 3–10.
27. Ding, W. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. Int J Clin Exp Med, 2015, Vol.8, no.1, pp. 322–33.
28. Kim, M. C. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2019; 98(6):1–9.
Review
For citations:
Kozlova I.V., Lapteva E.A., Bykova A.P., Pakhomova A.L. Components of the diff use endocrine system of the gastrointestinal tract and nonalcoholic fatty liver disease: interconnections and mutual infl uences. Experimental and Clinical Gastroenterology. 2020;174(5):53-60. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-177-5-53-60
Views:
425
Email this article 